Search

Search Constraints

You searched for: Author/Creator Tak, Paul Peter

Search Results

2. BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells. (November 2016)

3. BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells. (November 2016)

4. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Issue 7 (14th February 2007)

5. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Issue 6 (3rd May 2010)

6. CTIM-09. ENRICHED TCR/BCR VDJ REARRANGEMENTS CORRELATE WITH MRI AND SURVIVAL OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH CAN-3110. (14th November 2022)

7. CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). (12th November 2021)

8. DNA Methylome Signature in Synoviocytes From Patients With Early Rheumatoid Arthritis Compared to Synoviocytes From Patients With Longstanding Rheumatoid Arthritis. Issue 7 (July 2015)

10. OP0228 GSK3196165 AN INVESTIGATIONAL ANTI-GM-CSF MONOCLONAL ANTIBODY, IMPROVES PATIENT REPORTED OUTCOMES IN A PHASE IIB STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA). (June 2019)